Trial Profile
An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jul 2022
Price :
$35
*
At a glance
- Drugs Deutetrabenazine (Primary)
- Indications Drug-induced dyskinesia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms RIM-TD
- Sponsors Auspex Pharmaceuticals
- 10 Jun 2022 Results of a post hoc analysis of OLE study assessed long-term efficacy and safety of DTBZ in postmenopausal women presented at the 175th Annual Meeting of the American Psychiatric Association
- 26 Apr 2022 Results of post hoc analysis assessing dosing patterns by severity of tardive dyskinesia (TD) according to baseline Abnormal Involuntary Movement Scale (AIMS) item 8 score presented at the 74th Annual Meeting of the American Academy of Neurology 2022
- 26 Apr 2022 Results of post hoc analysis assessing long term safety and efficacy presented at the 74th Annual Meeting of the American Academy of Neurology 2022